文献速递妇科

曲妥珠单抗-美坦新偶联物(T-DM1)在HER2/neu高表达上皮性卵巢癌中体外和体内活性优于曲妥珠单抗、帕妥珠单抗及其联合方案

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
PubMed 文献 · Gynecol Oncol · 2017-07-10

该临床前研究比较了曲妥珠单抗(T)、帕妥珠单抗(P)、T+P联合及T-DM1对HER2/neu高表达上皮性卵巢癌的抗肿瘤活性,发现40%的原代细胞系为3+高表达,T-DM1在诱导凋亡和体内抑制肿瘤生长方面均优于T+P或单药,作者据此支持设计T-DM1治疗化疗耐药且HER2/neu过表达上皮性卵巢癌的临床研究。

要点

  • 40%的原代上皮性卵巢癌细胞系检测到3+ HER2/neu高表达。
  • T-DM1诱导的凋亡显著多于T+P(p<0.0001)。
  • T-DM1体内抑制肿瘤生长显著优于T、P及T+P(p=0.04)。

核心结论

  • 在3+ HER2/neu表达的上皮性卵巢癌体外和体内实验中,T或P单药抗肿瘤活性有限,T-DM1抗肿瘤活性优于T和P单药及T+P联合。
  • 作者的临床前数据支持设计T-DM1治疗化疗耐药且HER2/neu过表达上皮性卵巢癌的临床研究。

研究设计与样本

  • 研究建立原代上皮性卵巢癌细胞系并分析HER2/neu表达,体外评估T、P、T+P和T-DM1的细胞静止、凋亡和抗体依赖细胞介导的细胞毒作用(ADCC)活性,并在3+ HER2/neu表达的异种移植模型中测试体内抗肿瘤活性。

主要发现

  • 40%的原代上皮性卵巢癌细胞系检测到3+ HER2/neu高表达。
  • T、P、T+P和T-DM1在诱导针对表达3+ HER2/neu的原代上皮性卵巢癌细胞系的强ADCC方面效果相似。
  • T+P联合的细胞静止作用强于T单药(p<0.0001)和P单药(p<0.0001)。
  • T-DM1诱导的凋亡显著多于T+P(p<0.0001)。
  • 在过表达HER2/neu的上皮性卵巢癌异种移植模型中,T-DM1抑制肿瘤生长的效果显著优于T单药、P单药和T+P(p=0.04)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. The objective of this study was to compare the anti-tumor activity of HER2/neu-targeting monoclonal antibodies, trastuzumab (T), pertuzumab (P), combination of trastuzumab and pertuzumab (T+P) and trastuzumab-emtansine (T-DM1) in EOC with high HER2/neu expression. METHODS: Primary EOC cell lines were established and cell blocks were analyzed for HER2/neu expression. Cytostatic, apoptotic and antibody-dependent cell-mediated cytotoxicity (ADCC) activities of T, P, T+P and T-DM1 were evaluated in vitro. The in vivo antitumor activity was tested in xenograft models with 3+ HER2/neu expression. RESULTS: High (3+) HER2/neu expression was detected in 40% of the primary EOC cell lines. T, P, T+P, and T-DM1 were similarly effective in inducing strong ADCC against primary EOC cell lines expressing 3+ HER2/neu. The combination of T and P was more cytostatic when compared with that of T or P used alone (p<0.0001 and p<0.0001, respectively). T-DM1 induced significantly more apoptosis when compared with T+P (p<0.0001). Finally, T-DM1 was significantly more effective in tumor growth inhibition in vivo in EOC xenografts overexpressing HER2/neu when compared to T alone, P alone and T+P (p=0.04). CONCLUSION: In vitro and in vivo experiments with 3+ HER2/neu expressing EOC revealed limited anti-tumor activity of T or P. T-DM1 showed superior anti-tumor activity to T and P as single agents and as a combination. Our preclinical data support the design of clinical studies with T-DM1 for the treatment of chemotherapy-resistant EOC overexpressing HER2/neu.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Menderes G, Bonazzoli E, Bellone S, et al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017. PMID: 28705408. doi:10.1016/j.ygyno.2017.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。